;PMID: 9927037 ;source_file_1367.mrg ;Release 0.9 of PennBioIE ;Funded by NSF ITR EIA-0205448 ;0)section:[e:0..36] = [t:0..36] ;1)sentence:[e:41..170] = [t:41..170] ;2)section:[e:174..326] = [t:174..326] ;3)section:[e:330..436] = [t:330..436] ;4)sentence:[e:440..596] = [t:440..596] ;5)sentence:[e:597..776] = [t:597..776] ;6)sentence:[e:777..977] = [t:777..977] ;7)sentence:[e:978..1219] = [t:978..1219] ;8)sentence:[e:1220..1379] = [t:1220..1379] ;9)section:[e:1383..1427] = [t:1383..1427] ;section 0 Span:0..36 ;Cancer Res 1999 Jan 15;59(2):307-10 (SEC (FRAG (NN:[0..6] Cancer) (NNP:[7..10] Res) (CD:[12..16] 1999) (NNP:[17..20] Jan) (CD:[21..27] 15;59-LRB-) (CD:[27..28] 2) (-RRB-:[28..29] -RRB-) (CD:[29..33] :307) (NN:[33..34] -) (CD:[34..36] 10))) ;sentence 1 Span:41..170 ;Somatic mutations in the kinase domain of the Met/hepatocyte growth factor ;receptor gene in childhood hepatocellular carcinomas. ;[66..72]:gene-protein:"kinase" ;[87..90]:gene-rna:"Met" ;[91..125]:gene-rna:"hepatocyte growth factor receptor" ;[134..169]:malignancy:"childhood hepatocellular carcinomas" (SENT (NP-HLN (NP (JJ:[41..48] Somatic) (NNS:[49..58] mutations)) (PP (IN:[59..61] in) (NP (NP (DT:[62..65] the) (NN:[66..72] kinase) (NN:[73..79] domain)) (PP (IN:[80..82] of) (NP (DT:[83..86] the) (NML (NN:[87..90] Met) (SYM:[90..91] /) (NN:[91..101] hepatocyte)) (NML (NN:[102..108] growth) (NN:[109..115] factor) (NN:[117..125] receptor)) (NN:[126..130] gene))))) (PP (IN:[131..133] in) (NP (NN:[134..143] childhood) (JJ:[144..158] hepatocellular) (NNS:[159..169] carcinomas))) (.:[169..170] .))) ;section 2 Span:174..326 ;Park WS, Dong SM, Kim SY, Na EY, Shin MS, Pi JH, Kim BJ, Bae JH, Hong YK, Lee ; KS, Lee SH, Yoo NJ, Jang JJ, Pack S, Zhuang Z, Schmidt L, Zbar B, Lee JY. (SEC (FRAG (NNP:[174..178] Park) (NNP:[179..181] WS) (,:[181..182] ,) (NNP:[183..187] Dong) (NNP:[188..190] SM) (,:[190..191] ,) (NNP:[192..195] Kim) (NNP:[196..198] SY) (,:[198..199] ,) (NNP:[200..202] Na) (NNP:[203..205] EY) (,:[205..206] ,) (NNP:[207..211] Shin) (NNP:[212..214] MS) (,:[214..215] ,) (NNP:[216..218] Pi) (NNP:[219..221] JH) (,:[221..222] ,) (NNP:[223..226] Kim) (NNP:[227..229] BJ) (,:[229..230] ,) (NNP:[231..234] Bae) (NNP:[235..237] JH) (,:[237..238] ,) (NNP:[239..243] Hong) (NNP:[244..246] YK) (,:[246..247] ,) (NNP:[248..251] Lee) (NNP:[253..255] KS) (,:[255..256] ,) (NNP:[257..260] Lee) (NNP:[261..263] SH) (,:[263..264] ,) (NNP:[265..268] Yoo) (NNP:[269..271] NJ) (,:[271..272] ,) (NNP:[273..277] Jang) (NNP:[278..280] JJ) (,:[280..281] ,) (NNP:[282..286] Pack) (NNP:[287..289] S,) (NNP:[290..296] Zhuang) (NNP:[297..298] Z) (,:[298..299] ,) (NNP:[300..307] Schmidt) (NNP:[308..310] L,) (NNP:[311..315] Zbar) (NNP:[316..317] B) (,:[317..318] ,) (NNP:[319..322] Lee) (NNP:[323..325] JY) (.:[325..326] .))) ;section 3 Span:330..436 ;Department of Pathology and Cancer Research Institute, Catholic University ;Medical College, Seoul, Korea. (SEC (FRAG (NNP:[330..340] Department) (IN:[341..343] of) (NNP:[344..353] Pathology) (CC:[354..357] and) (NNP:[358..364] Cancer) (NNP:[365..373] Research) (NNP:[374..383] Institute) (IN:[383..384] ,) (NNP:[385..393] Catholic) (NNP:[394..404] University) (NNP:[406..413] Medical) (NNP:[414..421] College) (,:[421..422] ,) (NNP:[423..428] Seoul) (,:[428..429] ,) (NNP:[430..435] Korea) (.:[435..436] .))) ;sentence 4 Span:440..596 ;The MET protooncogene encodes a transmembrane tyrosine kinase identified as ;the receptor of a polypeptide known as hepatocyte growth factor/scatter ;factor. ;[444..447]:gene-rna:"MET" ;[486..501]:gene-protein:"tyrosine kinase" ;[556..580]:gene-protein:"hepatocyte growth factor" ;[581..595]:gene-protein:"scatter factor" (SENT (S (NP-SBJ (DT:[440..443] The) (NN:[444..447] MET) (NN:[448..461] protooncogene)) (VP (VBZ:[462..469] encodes) (NP (NP (DT:[470..471] a) (JJ:[472..485] transmembrane) (NN:[486..494] tyrosine) (NN:[495..501] kinase)) (VP (VBN:[502..512] identified) (NP (-NONE-:[512..512] *)) (PP (IN:[513..515] as) (NP (NP (DT:[516..519] the) (NN:[521..529] receptor)) (PP (IN:[530..532] of) (NP (NP (DT:[533..534] a) (NN:[535..546] polypeptide)) (VP (VBN:[547..552] known) (NP (-NONE-:[552..552] *)) (PP (IN:[553..555] as) (NP (NML (NN:[556..566] hepatocyte) (NN:[567..573] growth) (NN:[574..580] factor)) (SYM:[580..581] /) (NML (NN:[581..588] scatter) (NN:[589..595] factor)))))))))))) (.:[595..596] .))) ;sentence 5 Span:597..776 ;We performed PCR-based single-strand conformational polymorphism and ;sequencing analysis of the tyrosine kinase domain of the MET gene (exon ;15-19) in 75 primary liver cancers. ;[695..710]:gene-protein:"tyrosine kinase" ;[725..728]:gene-rna:"MET" ;[735..745]:variation-location:"exon 15-19" ;[754..775]:malignancy:"primary liver cancers" (SENT (S (NP-SBJ (PRP:[597..599] We)) (VP (VBD:[601..610] performed) (NP (NP (ADJP (NN:[611..614] PCR) (HYPH:[614..615] -) (VBN:[615..620] based)) (NML (JJ:[621..627] single) (HYPH:[627..628] -) (NN:[628..634] strand)) (JJ:[635..649] conformational) (NN:[650..662] polymorphism)) (CC:[663..666] and) (NP (NP (NN:[667..677] sequencing) (NN:[679..687] analysis)) (PP (IN:[688..690] of) (NP (NP (DT:[691..694] the) (NN:[695..703] tyrosine) (NN:[704..710] kinase) (NN:[711..717] domain)) (PP (IN:[718..720] of) (NP (DT:[721..724] the) (NN:[725..728] MET) (NN:[729..733] gene))) (PRN (-LRB-:[734..735] -LRB-) (NP (NP (NML-1 (NN:[735..739] exon)) (CD:[740..742] 15)) (PP (HYPH:[742..743] -) (NP (NML-1 (-NONE-:[743..743] *P*)) (CD:[743..745] 19)))) (-RRB-:[745..746] -RRB-)))))) (PP-LOC (IN:[747..749] in) (NP (CD:[750..752] 75) (JJ:[754..761] primary) (NN:[762..767] liver) (NNS:[768..775] cancers)))) (.:[775..776] .))) ;sentence 6 Span:777..977 ;Three missense mutations were detected exclusively in 10 childhood ;hepatocellular carcinomas (HCCs), while no mutations were detected in 16 ;adult HCCs, 21 cholangiocarcinomas, or 28 hepatoblastomas. ;[783..801]:variation-type:"missense mutations" ;[835..870]:malignancy:"childhood hepatocellular carcinomas" ;[872..876]:malignancy:"HCCs" ;[919..929]:malignancy:"adult HCCs" ;[934..953]:malignancy:"cholangiocarcinomas" ;[961..976]:malignancy:"hepatoblastomas" (SENT (S (NP-SBJ-1 (CD:[777..782] Three) (JJ:[783..791] missense) (NNS:[792..801] mutations)) (VP (VBD:[802..806] were) (VP (VBN:[807..815] detected) (NP-1 (-NONE-:[815..815] *)) (ADVP (RB:[816..827] exclusively)) (PP (IN:[828..830] in) (NP (CD:[831..833] 10) (NN:[835..844] childhood) (NML (NML (JJ:[845..859] hepatocellular) (NNS:[860..870] carcinomas)) (NML (-LRB-:[871..872] -LRB-) (NNS:[872..876] HCCs) (-RRB-:[876..877] -RRB-))))) (,:[877..878] ,) (SBAR-ADV (IN:[879..884] while) (S (NP-SBJ-2 (DT:[885..887] no) (NNS:[888..897] mutations)) (VP (VBD:[898..902] were) (VP (VBN:[903..911] detected) (NP-2 (-NONE-:[911..911] *)) (PP-LOC (IN:[912..914] in) (NP (NP (CD:[916..918] 16) (JJ:[919..924] adult) (NNS:[925..929] HCCs)) (,:[929..930] ,) (NP (CD:[931..933] 21) (NNS:[934..953] cholangiocarcinomas)) (,:[953..954] ,) (CC:[955..957] or) (NP (CD:[958..960] 28) (NNS:[961..976] hepatoblastomas)))))))))) (.:[976..977] .))) ;sentence 7 Span:978..1219 ;The extremely short incubation period from hepatitis B virus infection to ;the genesis of childhood HCC as compared with the adult HCC suggests that ;there may be an additional mechanism that accelerates the carcinogenesis of ;childhood HCC. ;[1022..1049]:malignancy:"hepatitis B virus infection" ;[1069..1082]:malignancy:"childhood HCC" ;[1104..1113]:malignancy:"adult HCC" ;[1205..1218]:malignancy:"childhood HCC" (SENT (S (NP-SBJ (NP (NP (DT:[978..981] The) (ADJP (RB:[982..991] extremely) (JJ:[993..998] short)) (NN:[999..1009] incubation) (NN:[1010..1016] period)) (PP (IN:[1017..1021] from) (NP (NML (NN:[1022..1031] hepatitis) (NN:[1032..1033] B)) (NN:[1034..1039] virus) (NN:[1040..1049] infection))) (PP (TO:[1050..1052] to) (NP (NP (DT:[1053..1056] the) (NN:[1057..1064] genesis)) (PP (IN:[1065..1067] of) (NP (NN:[1069..1078] childhood) (NN:[1079..1082] HCC)))))) (SBAR (IN:[1083..1085] as) (S (NP-SBJ-2 (-NONE-:[1085..1085] *)) (VP (VBN:[1086..1094] compared) (NP-2 (-NONE-:[1094..1094] *)) (PP-CLR (IN:[1095..1099] with) (NP (DT:[1100..1103] the) (JJ:[1104..1109] adult) (NN:[1110..1113] HCC))))))) (VP (VBZ:[1114..1122] suggests) (SBAR (IN:[1123..1127] that) (S (NP-SBJ (EX:[1128..1133] there)) (VP (MD:[1134..1137] may) (VP (VB:[1138..1140] be) (NP-PRD (NP (DT:[1141..1143] an) (JJ:[1145..1155] additional) (NN:[1156..1165] mechanism)) (SBAR (WHNP-1 (WDT:[1166..1170] that)) (S (NP-SBJ-1 (-NONE-:[1170..1170] *T*)) (VP (VBZ:[1171..1182] accelerates) (NP (NP (DT:[1183..1186] the) (NN:[1187..1201] carcinogenesis)) (PP (IN:[1202..1204] of) (NP (NN:[1205..1214] childhood) (NN:[1215..1218] HCC))))))))))))) (.:[1218..1219] .))) ;sentence 8 Span:1220..1379 ;Our results indicate that mutations of the tyrosine kinase domain of the MET ;gene may be involved in the acceleration of the carcinogenesis in childhood ;HCC. ;[1264..1279]:gene-protein:"tyrosine kinase" ;[1294..1297]:gene-rna:"MET" ;[1365..1378]:malignancy:"childhood HCC" (SENT (S (NP-SBJ (PRP$:[1220..1223] Our) (NNS:[1225..1232] results)) (VP (VBP:[1233..1241] indicate) (SBAR (IN:[1242..1246] that) (S (NP-SBJ-1 (NP (NNS:[1247..1256] mutations)) (PP (IN:[1257..1259] of) (NP (NP (DT:[1260..1263] the) (NN:[1264..1272] tyrosine) (NN:[1273..1279] kinase) (NN:[1280..1286] domain)) (PP (IN:[1287..1289] of) (NP (DT:[1290..1293] the) (NN:[1294..1297] MET) (NN:[1298..1302] gene)))))) (VP (MD:[1304..1307] may) (VP (VB:[1308..1310] be) (VP (VBN:[1311..1319] involved) (NP-1 (-NONE-:[1319..1319] *)) (PP-CLR (IN:[1320..1322] in) (NP (NP (DT:[1323..1326] the) (NN:[1327..1339] acceleration)) (PP (IN:[1340..1342] of) (NP (DT:[1343..1346] the) (NN:[1347..1361] carcinogenesis))) (PP (IN:[1362..1364] in) (NP (NN:[1365..1374] childhood) (NN:[1375..1378] HCC))))))))))) (.:[1378..1379] .))) ;section 9 Span:1383..1427 ;PMID: 9927037 [PubMed - indexed for MEDLINE] (SEC (FRAG (NNP:[1383..1387] PMID) (::[1387..1388] :) (CD:[1389..1396] 9927037) (-LRB-:[1397..1398] -LSB-) (NNP:[1398..1404] PubMed) (HYPH:[1405..1406] -) (NN:[1407..1414] indexed) (IN:[1415..1418] for) (NNP:[1419..1426] MEDLINE) (-RRB-:[1426..1427] -RSB-)))